| Windsor El Camino Care Center | |
| 2540 Carmichael Way, Carmichael, California 95608 | |
| (916) 482-0465 | |
| Name | Windsor El Camino Care Center |
|---|---|
| Location | 2540 Carmichael Way, Carmichael, California |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 178 |
| Occupancy Rate | 80.67% |
| Medicare ID (CCN) | 055402 |
| Legal Business Name | Windsor El Camino Care Center, Llc |
| Ownership Type | For Profit - Limited Liability Company |
| NPI Number | 1316083025 |
| Organization Name | WINDSOR EL CAMINO CARE CENTER, LLC |
| Doing Business As | WINDSOR EL CAMINO CARE CENTER |
| Address | 2540 Carmichael Way, Carmichael, CA 95608 |
| Phone Number | 916-482-0465 |
News Archive
Evotec AG today announced the start of the proof-of-concept Phase II study in treatment-resistant depression with its NR2B subtype selective NMDA receptor antagonist EVT 101. This clinical development is part of an alliance between Evotec and Roche.
A systematic review and meta-analysis carried out by researchers at the University of Exeter Peninsula College of Medicine and Dentistry has found that differences in systolic blood pressure between arms could be a useful indicator of the likelihood of vascular risk and death.
Efforts to combat the rapid spread of Zika virus got a boost this week as researchers at the University of Texas Medical Branch, Galveston (UTMB) announced the first peer-reviewed publication of a mouse model for Zika infection reported in decades.
A new Swedish study published in the journal Neurology shows that the risk of developing dementia may have declined over the past 20 years, in direct contrast to what many previously assumed.
› Verified 7 days ago
| NPI Number | 1841219011 |
| Organization Name | HELIOS HEALTHCARE, LLC |
| Doing Business As | EL CAMINO CARE CENTER |
| Address | 2540 Carmichael Way, Carmichael, CA 95608 |
| Phone Number | 916-482-0465 |
News Archive
Evotec AG today announced the start of the proof-of-concept Phase II study in treatment-resistant depression with its NR2B subtype selective NMDA receptor antagonist EVT 101. This clinical development is part of an alliance between Evotec and Roche.
A systematic review and meta-analysis carried out by researchers at the University of Exeter Peninsula College of Medicine and Dentistry has found that differences in systolic blood pressure between arms could be a useful indicator of the likelihood of vascular risk and death.
Efforts to combat the rapid spread of Zika virus got a boost this week as researchers at the University of Texas Medical Branch, Galveston (UTMB) announced the first peer-reviewed publication of a mouse model for Zika infection reported in decades.
A new Swedish study published in the journal Neurology shows that the risk of developing dementia may have declined over the past 20 years, in direct contrast to what many previously assumed.
› Verified 7 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Evotec AG today announced the start of the proof-of-concept Phase II study in treatment-resistant depression with its NR2B subtype selective NMDA receptor antagonist EVT 101. This clinical development is part of an alliance between Evotec and Roche.
A systematic review and meta-analysis carried out by researchers at the University of Exeter Peninsula College of Medicine and Dentistry has found that differences in systolic blood pressure between arms could be a useful indicator of the likelihood of vascular risk and death.
Efforts to combat the rapid spread of Zika virus got a boost this week as researchers at the University of Texas Medical Branch, Galveston (UTMB) announced the first peer-reviewed publication of a mouse model for Zika infection reported in decades.
A new Swedish study published in the journal Neurology shows that the risk of developing dementia may have declined over the past 20 years, in direct contrast to what many previously assumed.
› Verified 7 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 2.39 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 3.28 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 12.03 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0.43 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 0 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 0.67 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 0.4 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 11.19 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 98.83 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 1.24 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 18.69 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 9.64 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 7.87 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 99.48 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 57 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 90.01 | 82.93 |
News Archive
Evotec AG today announced the start of the proof-of-concept Phase II study in treatment-resistant depression with its NR2B subtype selective NMDA receptor antagonist EVT 101. This clinical development is part of an alliance between Evotec and Roche.
A systematic review and meta-analysis carried out by researchers at the University of Exeter Peninsula College of Medicine and Dentistry has found that differences in systolic blood pressure between arms could be a useful indicator of the likelihood of vascular risk and death.
Efforts to combat the rapid spread of Zika virus got a boost this week as researchers at the University of Texas Medical Branch, Galveston (UTMB) announced the first peer-reviewed publication of a mouse model for Zika infection reported in decades.
A new Swedish study published in the journal Neurology shows that the risk of developing dementia may have declined over the past 20 years, in direct contrast to what many previously assumed.
› Verified 7 days ago
Windsor El Camino Care Center Location: 2540 Carmichael Way, Carmichael, California 95608 Phone: (916) 482-0465 | |
River Pointe Post-acute Location: 6041 Fair Oaks Blvd, Carmichael, California 95608 Phone: (916) 483-8103 | |
Mission Carmichael Healthcare Center Location: 3630 Mission Avenue, Carmichael, California 95608 Phone: (916) 488-1580 | |
Whitney Oaks Care Center Location: 3529 Walnut Avenue, Carmichael, California 95608 Phone: (916) 488-8601 | |
Eskaton Care Center Manzanita Location: 5318 Manzanita Avenue, Carmichael, California 95608 Phone: (916) 331-8513 | |
American River Center Location: 3900 Garfield Avenue, Carmichael, California 95608 Phone: (916) 481-6455 |